Cargando…
Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis
BACKGROUND: The risk of prostate cancer-specific mortality (PCSM) following a diagnosis of prostate cancer may improve after patients have survived a number of years after diagnosis. We sought to determine long-term conditional PCSM for patients with stage T4, N1, or M1 prostate cancer. METHODS: We...
Autores principales: | Muralidhar, Vinayak, Mahal, Brandon A., Nguyen, Paul L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518568/ https://www.ncbi.nlm.nih.gov/pubmed/26220664 http://dx.doi.org/10.1186/s13014-015-0470-0 |
Ejemplares similares
-
Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
por: Muralidhar, Vinayak, et al.
Publicado: (2016) -
Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer()
por: Sinha, Sumi, et al.
Publicado: (2017) -
Geographic Distribution of Racial Differences in Prostate Cancer Mortality
por: Fletcher, Sean A., et al.
Publicado: (2020) -
NGF – the TrkA to successful pain treatment
por: Kumar, Vinayak, et al.
Publicado: (2012) -
Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis
por: Kan, Hung-Cheng, et al.
Publicado: (2017)